Mineralys Therapeutics News and Activities

Mineralys Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Mineralys Therapeutics is a company listed under the stock ticker MLYS (US).

View the org chart displaying its 28 main executives

Most searched biographies at Mineralys Therapeutics

• Jon Congleton, Chief Executive Officer
• Daphne Karydas, Director
• BT Slingsby, Director

Popular executive movements at Mineralys Therapeutics

• Jeffrey Munsie has joined the company as Chief Legal Officer  (posted on March 24 2026).

Create your alert
to follow the executive moves at Mineralys Therapeutics.

Mineralys Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Mineralys Therapeutics

• Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
• Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
• Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
• Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
• Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
• Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
• Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
• Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
• View more press releases Close

Social media about Mineralys Therapeutics

• Mineralys Therapeutics on Wikipedia, Google News & Yahoo Finance
• Mineralys Therapeutics on LinkedIn, X (Twitter) & YouTube